Results 181 to 190 of about 421,250 (298)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon   +10 more
wiley   +1 more source

Trends in lipoprotein(a) testing and impact on clinical care: A contemporary systemwide analysis. [PDF]

open access: yesAm J Prev Cardiol
Mangla M   +9 more
europepmc   +1 more source

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 809-818, April 2025.
Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Alessia Argirò   +20 more
wiley   +1 more source

EACVI Survey on the Current Multi-Modality Imaging Practice in Patients with Tricuspid Regurgitation. [PDF]

open access: yesEur Heart J Imaging Methods Pract
Muraru D   +23 more
europepmc   +1 more source

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray   +2 more
wiley   +1 more source

Outpatient treatment of decompensated heart failure: A systematic review and study level meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 761-769, April 2025.
Abstract Patients with acutely decompensated heart failure (ADHF) are usually admitted to hospital for management. There is growing interest in delivering intravenous (IV) diuretic therapy at home, in the community or at hospital day‐care units; the safety and effectiveness of outpatient‐based management (OPM) for ADHF has not been established.
Jameela Bahar   +13 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy